{
  "docId": "019dd923-622c-750b-8b98-be9011f05a27",
  "docSlug": "1cbf7684bf7d",
  "documentTitle": "Penumbra, Inc. (PEN)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-07-31 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 56,
  "pageCount": 61,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "comparison_table",
  "function": "expose_gap",
  "density": "balanced",
  "nDataPoints": 66,
  "notes": "The table uses red boxes to highlight the Spruce Point estimates that differ from the sell-side consensus.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "callout_box",
    "comparison_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-be9011f05a27/56",
  "deckHref": "/decks/019dd923-622c-750b-8b98-be9011f05a27",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-be9011f05a27.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-be9011f05a27#slide-56",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Spruce Point believes that, with Penumbra U.S. Stroke revenue growth set to slow in the face of heavy competition, and with consensus peripheral thrombectomy sales expectations far too aggressive, company-wide sales growth is set to be cut almost in half from Street estimates, from FY19 through FY21.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-ee3a-7528-92b8-29002759300a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Revenue Growth, YoY: 10.1%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-ee3a-7528-92b8-2feba39e87a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.0017
      },
      "kind": "paragraph",
      "text": "Spruce Point believes that, with Penumbra U.S. Stroke revenue growth set to slow in the face of heavy competition, and with consensus peripheral thrombectomy sales expectations far too aggressive, company-wide sales growth is set to be cut almost in half from Street estimates, from FY19 through FY21.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d14f7798-46ad-4b27-bb93-893ee366039d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.96,
        "x": 0.02,
        "y": 0.0031
      },
      "kind": "table",
      "text": "Comparison table of Blended Sell-Side vs Spruce Point estimates for FY19E-FY21E across various revenue segments.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "014ff99e-a79b-4173-8786-e1bb1dcf20e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.31,
        "y": 0.03
      },
      "kind": "title",
      "text": "Summarizing The Sales Decline: Sales Growth Set To Be Cut Almost In Half",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ca598d6-867f-44c5-b37f-f3e01607bb4f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "a6778691-fad8-48e3-90f1-108f384c9035",
      "evidence": "Direct comparison of sell-side vs activist estimates",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 61,
      "from": 31,
      "beatId": "12d3c67f-b91e-48ff-a8d3-c9685144b586",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The document presents Spruce Point's conclusion of 40-55% downside risk in PEN shares.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}